Children as young as 5 can now receive the updated Covid booster shots that target the variant of the virus after the Centers for Disease Control and Prevention signed off on Wednesday.
The final OK, from CDC Director Dr. came only hours after the Food and Drug Administration authorized the updated shots.
The FDA authorized Pfizer-BioNTech's modified vaccine for kids 5 to 11. Moderna’s shot was cleared for kids 6 through 17.
Children who have received a two-dose primary series of any vaccine and those who've received a booster are eligible to get the updated boosters as long as two months have passed since their last dose, the FDA said in a statement...
These bivalent COVID-19 vaccines include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA component in common between the variant BA.4 and BA.5 lineages to provide better protection against COVID-19 caused by the variant. The mRNA in these vaccines is a specific piece of genetic material that instructs cells in the body to make the distinctive “spike” protein of the original virus strain and the variant lineages BA.4 and BA.5. The spike proteins of BA.4 and BA.5 are identical.
With today’s authorization, the Pfizer-BioNTech COVID-19 Vaccine is no longer authorized as a booster dose for individuals five through 11 years of age. Both the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine continue to be authorized for primary series administration in individuals six months of age and older.
For each of the bivalent COVID-19 vaccines authorized today, the FDA relied on immune response and safety data that it had previously evaluated from a clinical study in adults of a booster dose of a bivalent COVID-19 vaccine that contained a component of the original strain of SARS-CoV-2 and a component of omicron lineage BA.1. The FDA considers such data as relevant and supportive of vaccines containing a component of the variant BA.4 and BA.5 lineages. In addition, the FDA has evaluated and considered immune response and safety data from clinical studies of the mRNA COVID-19 vaccines, including as a booster dose in pediatric age groups. These data and real-world experience with the mRNA COVID-19 vaccines, which have been administered to millions of people, including young children, support the EUA of the bivalent COVID-19 vaccines in younger age groups.
The data for the Moderna COVID-19 Vaccine are relevant to the Moderna COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.
The fact sheets for both of the bivalent COVID-19 vaccines for recipients and caregivers and for healthcare providers include information about potential side effects, as well as the risks of myocarditis and pericarditis.
The amendments to the were issued to Moderna TX Inc. and Pfizer Inc.
Children as young as 5 can now receive the updated Covid booster shots that target the variant of the virus after the Centers for Disease Control and Prevention signed off on Wednesday.
The final OK, from CDC Director Dr. came only hours after the Food and Drug Administration authorized the updated shots.
The FDA authorized Pfizer-BioNTech's modified vaccine for kids 5 to 11. Moderna’s shot was cleared for kids 6 through 17.
Children who have received a two-dose primary series of any vaccine and those who've received a booster are eligible to get the updated boosters as long as two months have passed since their last dose, the FDA said in a statement...
These bivalent COVID-19 vaccines include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA component in common between the variant BA.4 and BA.5 lineages to provide better protection against COVID-19 caused by the variant. The mRNA in these vaccines is a specific piece of genetic material that instructs cells in the body to make the distinctive “spike” protein of the original virus strain and the variant lineages BA.4 and BA.5. The spike proteins of BA.4 and BA.5 are identical.
With today’s authorization, the Pfizer-BioNTech COVID-19 Vaccine is no longer authorized as a booster dose for individuals five through 11 years of age. Both the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine continue to be authorized for primary series administration in individuals six months of age and older.
For each of the bivalent COVID-19 vaccines authorized today, the FDA relied on immune response and safety data that it had previously evaluated from a clinical study in adults of a booster dose of a bivalent COVID-19 vaccine that contained a component of the original strain of SARS-CoV-2 and a component of omicron lineage BA.1. The FDA considers such data as relevant and supportive of vaccines containing a component of the variant BA.4 and BA.5 lineages. In addition, the FDA has evaluated and considered immune response and safety data from clinical studies of the mRNA COVID-19 vaccines, including as a booster dose in pediatric age groups. These data and real-world experience with the mRNA COVID-19 vaccines, which have been administered to millions of people, including young children, support the EUA of the bivalent COVID-19 vaccines in younger age groups.
The data for the Moderna COVID-19 Vaccine are relevant to the Moderna COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.
The fact sheets for both of the bivalent COVID-19 vaccines for recipients and caregivers and for healthcare providers include information about potential side effects, as well as the risks of myocarditis and pericarditis.
Thanking You For Visit This
Thanking You For Visit This
Thanking You For Visit This
Thanking You For Visit This
You must be logged in to post a comment.